Effects of a selective 5-HT1B/1D receptor agonist on spinal and trigeminal reflexes in the anaesthetized rabbit

被引:7
作者
Jenkins, S [1 ]
Richardson, B [1 ]
Clarke, RW [1 ]
机构
[1] Univ Nottingham, Sch Biosci, Div Anim Physiol, Loughborough LE12 5RD, Leics, England
关键词
migraine; nociception; trigeminal reflex; spinal reflex; withdrawal reflex; serotonin; 5-HT1B; 1D receptors;
D O I
10.1038/sj.bjp.0703649
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The effects of the 5-HT1B/1D receptor agonist L-741,604 on a trigeminally-mediated (law depressor) reflex and a spinally-mediated (flexion withdrawal) reflex have been compared between spinalized and intact, anaesthetized rabbits. 2 L-741,604 depressed the jaw depressor reflex dose-dependently in all animals, to a median of 5% (inter-quartile range, IQR, 3-28%, n=18) of pre-drug levels after a cumulative dose of 3.1 mu mol kg(-1) i.v. This effect was reversed by the 5-HT1B/1D antagonist GR 127,935 (1-2 mu mol kg(-1) i.v.). 3 The flexion withdrawal reflex was depressed by L-741,604 in non-spinalized animals, to a median of 22% (IQR 10-36%, n = 10) of pre-drug levels after the highest dose, an action that was reversed by GR 127,935. 4 In spinalized rabbits, L-741,604 up to 0.3 mu mol kg(-1) i.v. cumulative increased the flexion reflex to a median of 189% (IQR 169-198%, n = 8) of pre-drug controls. With higher doses the reflex decreased, so that after 3.1 mu mol kg(-1) it was 75% (IQR 55-96%) of pre-drug levels. Subsequent GR 127,935 increased reflexes to a median of 180% (IQR 136-219%) of controls. 5 L-741,604 increased arterial blood pressure and decreased heart rate in both preparations, effects that were reversed by GR 127,935. 6 Thus, when the spinal cord was intact L-741,604 inhibited spinal and trigeminal reflexes in the same way. Although spinalization enabled a non-5-HT1B/1D-mediated excitatory effect of L-741,604 on spinal reflexes, there was a clear inhibitory effect of the drug at high doses. These data suggest that L-741,604 inhibits spinal reflexes by increasing descending inhibition and by a direct action in the cord. The same processes could apply to inhibition of trigeminally-mediated events.
引用
收藏
页码:974 / 980
页数:7
相关论文
共 29 条
  • [1] CAMPBELL NC, 1985, ADV PAIN RES THER, P233
  • [2] Naratriptan: Biological profile in animal models relevant to migraine
    Connor, HE
    Feniuk, W
    Beattie, DT
    North, PC
    Oxford, AW
    Saynor, DA
    Humphrey, PPA
    [J]. CEPHALALGIA, 1997, 17 (03) : 145 - 152
  • [3] Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist
    Cumberbatch, MJ
    Williamson, DJ
    Mason, GS
    Hill, RG
    Hargreaves, RJ
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (06) : 1478 - 1486
  • [4] Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses
    Cumberbatch, MJ
    Hill, RG
    Hargreaves, RJ
    [J]. CEPHALALGIA, 1998, 18 (10) : 659 - 663
  • [5] Rizatriptan has central antinociceptive effects against durally evoked responses
    Cumberbatch, MJ
    Hill, RG
    Hargreaves, RJ
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 328 (01) : 37 - 40
  • [6] The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats
    Cumberbatch, MJ
    Hill, RG
    Hargreaves, RJ
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 362 (01) : 43 - 46
  • [7] IS MYOFASCIAL PAIN OF THE TEMPORAL MUSCLES RELIEVED BY ORAL SUMATRIPTAN - A CROSS-OVER PILOT-STUDY
    DAO, TTT
    LUND, JP
    REMILLARD, G
    LAVIGNE, GJ
    [J]. PAIN, 1995, 62 (02) : 241 - 244
  • [8] Acute management of migraine: triptans and beyond
    Diener, HC
    Limmroth, V
    [J]. CURRENT OPINION IN NEUROLOGY, 1999, 12 (03) : 261 - 267
  • [9] Positron emission tomography studies in headache
    Diener, HC
    [J]. HEADACHE, 1997, 37 (10): : 622 - 625
  • [10] A dual effect of 5-HT1B receptor stimulation on nociceptive dorsal horn neurones in rats
    Gjerstad, J
    Tjolsen, A
    Hole, K
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 335 (2-3) : 127 - 132